Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03229200 |
| Title | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | FDA approved |
| Variant Requirements | No |
| Sponsors | Pharmacyclics Switzerland GmbH |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | TUR | SWE | POL | NZL | ITA | HUN | GBR | FRA | ESP | CZE | CAN | AUS |